https://sputnikglobe.com/20210820/preliminary-data-of-astrazeneca-sputnik-light-joint-trial-shows-high-immunogenicity-rdif-says-1083667695.html
Preliminary Data of AstraZeneca, Sputnik Light Joint Trial Shows High Immunogenicity, RDIF Says
Preliminary Data of AstraZeneca, Sputnik Light Joint Trial Shows High Immunogenicity, RDIF Says
Sputnik International
MOSCOW (Sputnik) - The combination of AstraZeneca and Sputnik Light COVID-19 vaccines showed high immunogenicity according to preliminary data obtained during... 20.08.2021, Sputnik International
2021-08-20T08:09+0000
2021-08-20T08:09+0000
2021-08-20T08:09+0000
world
newsfeed
sputnik v vaccine
astrazeneca
russian direct investment fund (rdif)
vaccine
https://cdn1.img.sputnikglobe.com/img/07e5/03/03/1082239711_0:45:837:516_1920x0_80_0_0_2fd0734edec5e47e92c015b1e06335b0.jpg
"Clinical trials in Azerbaijan began in February 2021 ... Preliminary data from the first 20 participants shows antibodies to the SARS-CoV-2 virus spike protein (S-protein) elicited in 100% of cases. The interim analysis of data has previously demonstrated a high safety profile for the combined use of the vaccines with no serious adverse effects or cases of coronavirus infection after vaccination," the RDIF said in a press release.A memorandum of cooperation between Sputnik V developer Gamaleya Center, AstraZeneca, the RDIF and R-Pharm was signed in December 2020.The document assumes cooperation in the development and implementation of a clinical research program to evaluate the combined use of one of the components of the Sputnik V vaccine and one of the components of the AZD1222 vaccine, developed by AstraZeneca in cooperation with the University of Oxford.
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
2021
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
News
en_EN
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
newsfeed, sputnik v vaccine, astrazeneca, russian direct investment fund (rdif), vaccine
newsfeed, sputnik v vaccine, astrazeneca, russian direct investment fund (rdif), vaccine
Preliminary Data of AstraZeneca, Sputnik Light Joint Trial Shows High Immunogenicity, RDIF Says
MOSCOW (Sputnik) - The combination of AstraZeneca and Sputnik Light COVID-19 vaccines showed high immunogenicity according to preliminary data obtained during a clinical trial in Azerbaijan, the Russian Direct Investment Fund (RDIF) said on Friday.
"Clinical trials in Azerbaijan began in February 2021 ... Preliminary data from the first 20 participants shows antibodies to the SARS-CoV-2 virus spike protein (S-protein) elicited in 100% of cases. The interim analysis of data has previously demonstrated a high safety profile for the combined use of the vaccines with no serious adverse effects or cases of coronavirus infection after vaccination," the RDIF said in a press release.
A memorandum of cooperation between
Sputnik V developer Gamaleya Center, AstraZeneca, the RDIF and R-Pharm was signed in December 2020.
The document assumes
cooperation in the development and implementation of a clinical research program to evaluate the combined use of one of the components of the Sputnik V vaccine and one of the components of the AZD1222 vaccine, developed by AstraZeneca in cooperation with the University of Oxford.
